Large-scale association analysis identifies 13 new susceptibility loci for coronary artery diseaseStephen E. Epstein, Christian Gieger, Devin Absher et al.|Nature Genetics|2011Cited by 2k
Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5 H-benzocyclohepten-5-ol]: In Vitro StudiesBarbara Spagnolo, Girolamo Calò, Giacomo Carrà et al.|Journal of Pharmacology and Experimental Therapeutics|2007Cited by 97
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5‐hydroxytryptamine and noradrenaline release in the rat neocortexMatteo Marti, Michele Morari, Sara Stocchi et al.|British Journal of Pharmacology|2003Cited by 62
Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1?14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1?14)NH2Masato Kitayama, David G. Lambert, Timothy Barnes et al.|Naunyn-Schmiedeberg s Archives of Pharmacology|2003Cited by 21
Effects of [(pF)Phe4]nociceptin/orphanin FQ-(1–13)NH2 on GTPγ35S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptorJohn McDonald, David G. Lambert, Timothy Barnes et al.|European Journal of Pharmacology|2002Cited by 18